Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates The US Food and Drug Administration (FDA) has provided emergency expanded access to Bellerophon Therapeutics’ INOpulse for Covid-19 treatment.
INOpulse is an inhaled nitric oxide (iNO) delivery system. NO is a naturally produced molecule that plays a key role in the immune response against pathogens and infections.
According to in-vitro studies, NO blocks the replication of severe acute respiratory syndrome-related coronavirus (SARS-CoV) while improving the survival of infected cells.
In a clinical study involving SARS-CoV patients, iNO led to improvements in arterial oxygenation and lung infiltrates, along with a decrease in the requirement for